Advance in the Treatment of Ph Chromosome Positive Acute Lymphoblastic Leukemia ---Review.
10.19746/j.cnki.issn.1009-2137.2019.04.055
- Author:
Ming-Jie TIAN
1
;
Xiao-Kang XU
2
;
Song-Ying ZHAO
3
Author Information
1. Department of Hematology, The Afilliatied Hospital of Hebei Universtity， Baoding 071000, Hebei Province, China.
2. Medical College, Medical Department of Hebei University， Baoding 071000, Hebei Province, China.
3. Department of Hematology, The Afilliatied Hospital of Hebei Universtity， Baoding 071000, Hebei Province, China,E-mail: 820177315@qq.com.
- Publication Type:Journal Article
- MeSH:
Chromosomes;
Hematopoietic Stem Cell Transplantation;
Humans;
Philadelphia Chromosome;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Prognosis;
Protein Kinase Inhibitors
- From:
Journal of Experimental Hematology
2019;27(4):1325-1329
- CountryChina
- Language:Chinese
-
Abstract:
Abstract The curative efficacy of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL) has been improved substantially with the introduction of tyrosine kinase inhibitors (TKIs). However, there is no consensus so far on the following issues, which TKIs should be chosen in combination with chemotherapeutic regimens; which regimen of intensive chemotherapy incorporated into TKIs would be more beneficial to patients. The prognosis of the patients with Ph ALL has been so significantly improved by the combinatorial treatment of TKIs and chemotherapy, thus it is necessary to reevaluate the role of allogeneic hematopoietic stem cell transplantation in the management of Ph ALL. In addition, immunotherapy has achieved an initial success in the treatment of Ph ALL. In this review, the treatment paradigms for the disease are summrized briefly.
